Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: atticus4paws who wrote (12121)	1/17/2019 9:57:02 AM
From: scaram(o)uche	Respond to of 12215

urrrrrrrrrrrgh.............. it does read "with a 1.1% reduction in A1C at the 1.8 mg dose relative to placebo", rather than what I interpreted...... with a 1.1% reduction OF A1C at the 1.8 mg dose relative to placebo. Thanks! Belanorib was highly effective (but toxic), and the PR says that results "appear very competitive with the currently available best-in-class anti-diabetes therapies". So I'd suggest that they're either being very deceptive, or that, using your example, they meant 7% to 5.9%. But you're correct, given a literal reading.